Navigation Links
HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
Date:4/25/2012

c. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

Forward-Looking Statements

This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.  All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the timing and progress of, and presentation of data related to, clinical trials, expected timing of regulatory filings and approvals, and research and development activities.  Management believes that these forward-looking statements are reasonable as and when made.  However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made.  HeartWare does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  HeartWare may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.  Forward-looking statements are subject to a number of risks and uncertainties, including without limitation, the possibility the FDA does not approve the marketing of the HeartWare® Ventricular Assist System in the U.S., and those described in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission.  We may update our risk factors from time to time in Part II, Item 1A "Risk Factors" in our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, or other filings with the Securities an
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Presentation of HeartWare Clinical Results
2. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
3. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
4. HeartWare International Reports Third Quarter Revenues of $7.5 Million
5. HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
6. HeartWare to Present at the UBS 2010 Global Life Sciences Conference
7. HeartWare to Present at Lazard Capital Markets Circulatory Assist Device Day
8. HeartWare to Report Financial Results for Third Quarter of 2010
9. HeartWare International Reports Third Quarter 2010 Revenues of $13.8 Million; Compared to $7.5 Million in Third Quarter of 2009
10. HeartWare Bridge-to-Transplant Data Featured as Late Breaking Clinical Trial at American Heart Association Scientific Sessions 2010
11. HeartWare to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 Pepperl+Fuchs, a world ... MACTek Corporation, a leading provider of HART protocol ... to further extend its integrated solutions offerings and ... "We are pleased to add the ... said Jim Bolin , Pepperl+Fuchs, executive vice ...
(Date:8/31/2015)... 2015 Thousands of people will peacefully demonstrate ... opioid addiction epidemic at dozens of rallies across the ... the United States has experienced ... opioids and heroin, yet the President has never once ... letter to President Obama , rally organizers compared ...
(Date:8/31/2015)... , August 31, 2015 ... that the global cardiovascular monitoring and diagnostic devices ... is predicted to reach a value of approximately ... of 9.7% between 2013 and 2019. The title ... Devices Market (ECG, Holter Monitors, Event Monitors, Cardiovascular ...
Breaking Medicine Technology:Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5
... JERUSALEM , June 2, ... oral drug delivery systems, announced,today that its subsidiary Oramed Ltd. ... ("Laser Detect"), an Israeli company listed on,the Tel Aviv Stock ... Entera Bio Ltd. ("Entera"). Under the terms of the agreement, ...
... Questcor Pharmaceuticals, Inc . (Nasdaq: QCOR ) announced today that it ... June 10, 2010 at The Grand Hyatt Hotel in New York, ... will discuss the Company,s business strategy and historical financial performance at 11:30 ... , Attendance at ...
Cached Medicine Technology:Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 2Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 3Questcor to Present at the Jefferies 2010 Global Life Sciences Conference 2
(Date:9/1/2015)... Greifensee, Switzerland (PRWEB) , ... September 01, 2015 ... ... “Calibration and Qualification of Laboratory Instruments in accordance with GMP requirements“ , ... be presented on October 6th, 2015 at 11:00 EDT (15:00 GMT). , ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Mercy Health (formerly ... devoted the 10th of its monthly Mercy Health: Helping You Be Well videos to ... in seven men. , In a concise video on Mercy Health’s YouTube channel, ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... 9, 2015 from 5:00 to 8:00 pm at the Marriott Indianapolis Downtown, 350 ... with career opportunities will be attending from across the country. All specialties will ...
(Date:9/1/2015)... ... September 01, 2015 , ... Éminence Organic Skin Care ... VitaSkin™ Exfoliating Peels. This revolutionary collection of natural peel solutions complements the existing ... , Formulated with alpha hydroxy acids and natural active ingredients, these results-oriented ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... has established the MAP Recovery Network, the Premier Outcomes-Driven Provider Network. It ... rapidly-growing alliance is dedicated to the provision of quality addiction treatment and ...
Breaking Medicine News(10 mins):Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2Health News:New Mercy Health Video Explains Most-Common Cancer Found in Men 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 4Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 3Health News:MAP Health Management Launches the MAP Recovery Network 2
... Ill., and Rockville, Md., SAN JOSE, Calif., ... major fundraising events for the Coalition for Pulmonary,Fibrosis ... benefiting the,CPF collectively raised more than a half ... families fighting pulmonary fibrosis (PF) and,directly funds research. ...
... of Undergraduate and Graduate Programs, Now Offered at ... Board of Trustees, in,conjunction with President James J. Gozzo, ... its name to become Albany College,of Pharmacy and Health ... Board of Education, has been chosen to better reflect ...
... efficiently, study says , , THURSDAY, Oct. 16 (HealthDay News) ... the body, while being physically fit decreases it, according to ... 452 healthy men who had levels of different groups of ... cell count is a marker of inflammatory activity and is ...
... divorce, or even the loss of jobs or financial security, the mental ... inaccurate Stages Theory of Grief. At long last, Grief Recovery pioneers, Russell ... grief really is what it definitely isn,t. , ... Sherman Oaks, CA ...
... China, Oct. 16 /Xinhua-PRNewswire/ -- WuXi PharmaTech,(Cayman) ... pharmaceutical, biotechnology and,medical device research and development ... United States, today announced it has reached ... & Development, Division of,Janssen Pharmaceutica, N.V. (J&JPRD) ...
... 15 Young Innovations, Inc.,(Nasdaq: YDNT ) today ... with a live and on-demand web cast conference call ... live audio broadcast of the,call will be available through ... broadcast will also be available through the,Company,s website, ...
Cached Medicine News:Health News:CPF Fundraisers Bring in Landmark Half Million Dollars in Less Than Three Weeks 2Health News:CPF Fundraisers Bring in Landmark Half Million Dollars in Less Than Three Weeks 3Health News:Albany College of Pharmacy and Health Sciences - New Name, Same Commitment to the Advancement of Health Care 2Health News:Fatness Boosts Inflammation in Body 2Health News:Stages Of Grief Refuted As Inaccurate and Dangerous By Grief Recovery Institute Founders In Skeptic Magazine Article 2Health News:Stages Of Grief Refuted As Inaccurate and Dangerous By Grief Recovery Institute Founders In Skeptic Magazine Article 3Health News:Stages Of Grief Refuted As Inaccurate and Dangerous By Grief Recovery Institute Founders In Skeptic Magazine Article 4Health News:WuXi PharmaTech Expands Collaboration for Fully Integrated Services 2Health News:Young Innovations, Inc. Provides Third Quarter Conference Call Details 2
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
... are manufactured using the highest ... CQ UV PMMA material is ... single piece lenses. Unioptic lens ... nonphaco and phaco styles. All ...
... STAARVISC II is a sterile nonpyrogenic, ... hyaluronate. STAARVISC II contains 12 mg/ml of ... daltons) sodium hyaluronate dissolved in physiological saline. ... the viscosity is 105,000 cps (105 Pa ...
... viscoelastic agent for the surgeon who performs ... Amvisc possesses sufficient viscosity for excellent chamber ... cohesive so that complete removal at the ... quickly accomplished. Amvisc is priced to compete ...
Medicine Products: